Selective laser trabeculoplasty (SLT), an established first-line therapy for open-angle glaucoma and ocular hypertension, has limited evidence regarding its effectiveness after prior ocular hypotensive medications. To address this gap, an exploratory analysis evaluated SLT as a secondary treatment following three years of protocolized medical therapy, assessing its impact on intraocular pressure control in 633 participants. The analysis found that 35% of participants on primary ocular hypotensive drops ultimately received SLT, with those switching to SLT experiencing a significant reduction in medication use.
By 72 months, over 60% of eyes that switched required no further medical or surgical therapy, and more than 80% of eyes previously on a single drug remained medication-free. Among those escalated to SLT, intraocular pressure decreased by 21.8%, with nearly two-thirds reaching…
